ArticleOphthalmology and therapy2026
Benefit of Latanoprostene Bunod (Vyzulta) for Glaucoma Switched from Prior Pharmacotherapy: A Retrospective Cohort Study in Taiwan.
Article in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTopical prostaglandin analogs (PGAs) are used to treat glaucoma and provide significant reductions in intraocular pressure (IOP). This study evaluated the efficacy and safety of latanoprostene bunod 0.024% (LBN; Vyzulta
methodsThe records of patients treated at Kaohsiung Veterans General Hospital with glaucoma who were switched to LBN from conventional PGAs between November 2020 and December 2021 were retrospectively reviewed. IOP measurements were taken at baseline, 1 month, 3 months, and 6 months, and 1 year after switching. Outcomes included changes in IOP from baseline at each follow-up period, and adverse event evaluation. Repeated measures analysis of variance (ANOVA) tests and the generalized estimating equations (GEE) analyses were performed to estimate the effect of LBN on IOP reduction over time.
resultsA total of 87 patients (129 eyes) were included. Significant IOP reduction trends were noted across various subgroups, including patients with different initial IOP and different glaucoma types. GEE analysis showed significant IOP reductions in most subgroups, with the greatest reduction observed in patients with high initial IOP (estimate = -4.59, 95% confidence interval [CI] -6.9 to -3.0, p < 0.001). Adverse events occurred in 18% of patients, all of which were mild.
conclusionsIn this retrospective cohort of Taiwanese patients with glaucoma whose IOP remained inadequately controlled on prior PGAs therapy, switching to LBN was associated with a statistically significant, although modest, reduction in IOP over 12 months and a low rate of mild, non-serious ocular adverse events. These exploratory real-world findings provide hypothesis-generating evidence supporting LBN as a treatment option when further IOP reduction is needed and should be confirmed in larger prospective multicenter studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.